SCHEDULE: Vanguard Reports Zero Beneficial Ownership in Quest Diagnostics

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Quest Diagnostics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 13 to Schedule 13G for Quest Diagnostics Inc. Common Stock (CUSIP 74834L100).
• The filing reports 0.00 shares beneficially owned by The Vanguard Group, representing 0% of the class.
• This change is a result of an internal realignment within The Vanguard Group, Inc., which became effective on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• These subsidiaries and/or business divisions continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, procedural filing. It reflects an internal reporting adjustment by Vanguard and does not indicate a change in investment sentiment towards Quest Diagnostics itself.

Positives

• The filing indicates a clear, compliant reporting adjustment by a major institutional investor, adhering to SEC guidelines.
• The underlying investment strategies for Quest Diagnostics shares held by Vanguard's subsidiaries remain unchanged, implying no shift in investment thesis by Vanguard-managed funds.

Negatives

• The reduction to 0% beneficial ownership by the parent entity, while a reporting change, might be misinterpreted by some investors without understanding the context of the internal realignment.

Risks

• Potential for misinterpretation by investors regarding Vanguard's overall investment in Quest Diagnostics, as the 0% reported by the parent entity does not mean Vanguard-managed funds no longer hold shares.

Future Outlook

NA

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that this filing reflects a common practice among large, diversified asset managers like Vanguard to adjust their internal reporting structures for compliance and operational efficiency. The disaggregated reporting aligns with SEC guidance for complex organizational structures, ensuring transparency while allowing for internal operational changes. This is a procedural update rather than a change in investment thesis.

Comparison to Industry Standards

• This type of internal realignment and subsequent disaggregated reporting is consistent with practices observed among other large asset managers such as BlackRock or State Street, who also manage vast portfolios through various subsidiaries and funds.
• The reliance on SEC Release No. 34-39538 (January 12, 1998) is a standard compliance approach for such organizational changes, ensuring adherence to regulatory guidelines for beneficial ownership reporting.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (Quest Diagnostics): No direct impact on Quest Diagnostics' operations or financial performance. The change is purely a reporting adjustment by a major institutional investor.
• Investors (Vanguard Funds): No change to the underlying investment strategies or holdings within Vanguard-managed funds that invest in Quest Diagnostics. The change is administrative.

Next Steps

• Vanguard's subsidiaries or business divisions will now report their beneficial ownership of Quest Diagnostics shares separately in future filings.

Key Dates

Keywords

Vanguard Group, Quest Diagnostics, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Internal Realignment, Investment Management